Business Context and Reporting Period
Company: BioCardia, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 18, 2025
Principal Executive Offices: Sunnyvale, California
Trading Symbol: BCDA (Nasdaq Capital Market)
This filing serves as a Regulation FD disclosure regarding the announcement of primary endpoint results for the open-label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements or performance metrics.
Material Changes
Clinical Development Update:
- Announcement of primary endpoint results for the open-label roll-in cohort of the CardiAMP Cell Therapy trial.
- The trial focuses on Chronic Myocardial Ischemia.
No material changes to financial position or operations are detailed in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (attached as Exhibit 99.1) detailing the trial results. The filing itself does not contain specific management commentary, forward-looking guidance, or risk factors beyond the standard legal disclaimers regarding the non-filing status of the press release for Section 18 liability purposes.
Unusual Items: None reported in the text of the 8-K.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for the specific numerical data and statistical significance of the primary endpoint results.
- Verify the implications of the "open-label roll-in cohort" design on the validity and generalizability of the results.
- Check subsequent filings for any updated financial guidance or strategic shifts resulting from these clinical outcomes.
- Confirm the regulatory status of the CardiAMP Cell Therapy following this announcement.